Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if using the drugs Rituximab (IDEC-C2B8)
and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine) together is better
than using rituximab alone to treat follicular B-cell lymphomas. The safety of this treatment
will also be studied.